Harnessing MerTK agonism for targeted therapeutics

被引：10
|
作者：
Kedage, Vivekananda [1 ]
Ellerman, Diego [2 ]
Chen, Yongmei [3 ]
Liang, Wei-Ching [3 ]
Borneo, Joven [4 ]
Wu, Yan [3 ]
Yan, Minhong [1 ]
机构：
[1] Genentech Inc, Dept Mol Oncol, San Francisco, CA USA
[2] Genentech Inc, Dept Prot Chem, San Francisco, CA USA
[3] Genentech Inc, Dept Antibody Engn, San Francisco, CA USA
[4] Genentech Inc, Dept Immunol & Infect Dis, San Francisco, CA USA
来源：
MABS | 2020年 / 12卷 / 01期
关键词：
Phagocytosis; bispecific antibody; immunologically silent; MerTK; Fc gamma receptor;
D O I：
10.1080/19420862.2019.1685832
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Phagocytosis plays important roles both in homeostasis and under pathological conditions. Fc gamma receptor-mediated phagocytosis has been exploited as an integral mechanism for antibody-based therapies. Unlike Fc gamma receptor-mediated phagocytosis, MerTK-mediated phagocytic clearance is immunologically silent. Here, we describe a bispecific antibody approach to harness MerTK for targeted clearance without inducing proinflammatory cytokine release associated with Fc gamma receptor engagement. We generated bispecific antibodies targeting live B cells or amyloid beta aggregates to demonstrate the feasibility and versatility of this new approach.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Harnessing sortase A transpeptidation for advanced targeted therapeutics and vaccine engineering
    Obeng, Eugene M.
    Fulcher, Alex J.
    Wagstaff, Kylie M.
    BIOTECHNOLOGY ADVANCES, 2023, 64
  • [2] Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics
    Sarkar, Fazlul H.
    Li, Yiwei
    CANCER TREATMENT REVIEWS, 2009, 35 (07) : 597 - 607
  • [3] Targeted Delivery of Anticancer Therapeutics with Polymers by Harnessing Tumor Microenvironment Acidity
    Shi, Jiahao
    Ma, Bin
    Zhang, Yuhe
    Yong, Haiyang
    Li, Zhili
    Sigen, A.
    Huang, Xiaobei
    Zhou, Dezhong
    CHEMISTRY OF MATERIALS, 2023, 35 (17) : 6573 - 6590
  • [4] Harnessing telomerase in cancer therapeutics
    Fakhoury, Johans
    Nimmo, Graeme A. M.
    Autexier, Chantal
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2007, 7 (04) : 475 - 483
  • [5] MERTK Inhibition as a Targeted Novel Cancer Therapy
    Tanim, K. M.
    Holtzhausen, Alisha
    Thapa, Aashis
    Huelse, Justus M.
    Graham, Douglas K.
    Earp, H. Shelton
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [6] Targeted Therapeutics
    不详
    CELL, 2011, 147 (02) : 253 - 255
  • [7] Bioconjugates: Harnessing Potential for Effective Therapeutics
    Khare, Piush
    Jain, Aviral
    Gulbake, Arvind
    Soni, Vandana
    Jain, Nitin K.
    Jain, Sanjay K.
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2009, 26 (02): : 119 - 155
  • [8] Harnessing the potential of CD40 agonism in cancer therapy
    Zhou, Yang
    Richmond, Ann
    Yan, Chi
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 40 - 56
  • [9] The Synthesis and Initial Evaluation of MerTK Targeted PET Agents
    Wang, Li
    Zhou, Yubai
    Wu, Xuedan
    Ma, Xinrui
    Li, Bing
    Ding, Ransheng
    Stashko, Michael A.
    Wu, Zhanhong
    Wang, Xiaodong
    Li, Zibo
    MOLECULES, 2022, 27 (05):
  • [10] Integrin Targeted Therapeutics
    Millard, Melissa
    Odde, Srinivas
    Neamati, Nouri
    THERANOSTICS, 2011, 1 : 154 - 188
12345